您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Teicoplanin A3-1
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Teicoplanin A3-1
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Teicoplanin A3-1图片
CAS NO:93616-27-4
规格:98%
分子量:1564.3
包装与价格:
包装价格(元)
1mg电议
5mg电议

产品介绍
glycopeptide antibiotic
CAS:93616-27-4
分子式:C72H68Cl2N8O28
分子量:1564.3
纯度:98%
存储:Store at -20°C

Background:

Teicoplanin A3-1, also known as Antibiotic L 17054, is a glycopeptide antibiotic derived from Actinoplanes teichomyceticus and produces a potent broad spectrum antibiotic activity against gram-positive bacteria.


Teicoplanin A3-1 is a common degradation product of teicoplanins A2-1 to 5, which results from cleavage of the lipoaminoglycoside substituents. Teicoplanins are glycopeptide antibiotics produced by A. teichomyceticus which are effective against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and E. faecalis. As an antibiotic complex, teicoplanin consists of five closely related factors, T-A2-1, 2, 3, 4 and 5 and a more polar factor, T-A3-1. Additionally, as a glycopeptide antibiotic belonging to the same family as vancomycin, teicoplanin blocks cell wall synthesis in Bacillus subtilis, which is accompanied by an intracellular accumulation of UDP-N-acetylmuramyl-pentapetide [1]. Due to the greater antibacterial activity of teicoplanin than other agents, it has been thoroughly studied as a β-1actamase-resistant agent for the treatment of human infections caused by streptococci and staphylococci, including enterococci [2].


In vitro: Up to now, in vitro study of Teicoplanin A3-1 is still in the development stage.


In vivo: Up to now, in vivo study of Teicoplanin A3-1 is still in the development stage.


参考文献:
[1].  Somma, S., Gastaldo, L., & Corti, A. Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp. Antimicrobial Agents and Chemotherapy. 1984; 26(6): 917-923.
[2].  Traina, G., & Bonati, M. Pharmacokinetics of teicoplanin in man after intravenous administration. Journal of Pharmacokinetics and Biopharmaceutics. 1984;12(2): 119-128.